Latest Contracts News

Lotus Resources has launched a A$81 million equity raising to support the ramp-up of its Kayelekera uranium mine to steady state production targeted in Q2 2026, while advancing development of its Letlhakane project.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

NoviqTech Limited launches Coralia, a large-scale biochar carbon removal initiative aimed at helping data centres achieve net zero emissions while restoring the Great Barrier Reef catchment. The project taps into the booming carbon removal market driven by tech giants and environmental urgency.

Volt Resources has extended and significantly increased its graphite offtake agreement with Qingdao Baixing, aligning with the Bunyu project’s development timeline and production targets.

Elders Limited has announced René Dedoncker as its next CEO, set to begin in October 2026, with current CEO Mark Allison staying on through a transition period. Dedoncker brings two decades of agribusiness leadership experience from Fonterra and Mars Corporation.

Ainsworth Game Technology reveals a significant $43.1 million goodwill impairment tied to its North American operations, alongside other one-off losses, tempering its FY25 profit outlook.

SKS Technologies Group has upgraded its FY26 earnings forecast following $60 million in new contract awards, including major projects for NEXTDC and Ernst & Young. The company anticipates stronger revenue and profit margins driven by robust demand in data centre infrastructure.

Jcurve Solutions has reported a robust first half of FY26, posting a 32% increase in revenue and a remarkable 478% jump in EBITDA, while upgrading its full-year revenue guidance amid ongoing customer churn challenges.

RPMGlobal Holdings Limited shares will be suspended from the ASX following Federal Court approval of its acquisition by a Caterpillar subsidiary, marking a significant ownership change.

Garda Property Group reported a 16% rise in revenue and a 20% increase in funds from operations for the first half of 2026, while net profit after tax fell by nearly 24%. The group declared a steady interim distribution of 4 cents per security.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.